Phenylalanine supplementation improves the phenylalanine profile in tyrosinaemia.
Tyrosinaemia types I and II are caused by enzyme deficiencies in the tyrosine catabolism pathway. Successful treatment is possible with the novel enzyme inhibitor NTBC in tyrosinaemia type I and with dietary tyrosine and phenylalanine restriction in both conditions. This is achieved with a low natural protein intake and a supplementary amino acid formula that is phenylalanine- and tyrosine-free. Patients on this regimen had been noted, periodically, to have very low plasma phenylalanine concentrations (<20 micromol/L). The tyrosine and phenylalanine profiles in six patients were measured. Five of the six patients had very low concentrations of phenylalanine during the later half of the day. The response to phenylalanine supplementation was assessed and supplementing the diet with phenylalanine 30-40 mg/kg per day resulted in normal concentrations throughout the day. Possible complications of hypophenylalaninaemia and potential preventive treatment strategies are discussed. Further studies are needed to investigate the longer-term clinical and biochemical consequences of phenylalanine supplementation.
Wilson
C J
CJ
Metabolic Unit, Great Ormond Street Hospital for Children, London, UK. callumjwilson@yahoo.com
Van Wyk
K G
KG
Leonard
J V
JV
Clayton
P T
PT
D002648:Child; D002675:Child, Preschool; D019587:Dietary Supplements; D006801:Humans; D007223:Infant; D010649:Phenylalanine / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome; D014443:Tyrosine / Q000097:blood; D020176:Tyrosinemias / Q000097:blood / Q000188:drug therapy*
D014443:Tyrosine; D010649:Phenylalanine